The additional number of common stock to be issued under stock purchase agreement.

No definition available.

Name:	syn_AdditionalNumberOfCommonStockToBeIssued
Namespace Prefix:	syn_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount represents the fair value of shares issued.

+ References

No definition available.

+ Details

Name:	syn_FairValueOfSharesIssued
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The additional number of common stock to be held by the related party under stock purchase agreement.

+ References

No definition available.

+ Details

Name:	syn_NumberOfCommonStockToBeHeldByRelatedParty
Namespace Prefix:	syn_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The number of common stock to be issued under stock purchase agreement.

+ References

No definition available.

+ Details

Name:	syn_NumberOfCommonStockToBeIssued
Namespace Prefix:	syn_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The parent entity's interest in net assets of the subsidiary, expressed as a percentage.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of Net Income (Loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

+ Details

Name:	us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=syn_SYNBiomicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=syn_SyntheticBiomicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_DrPimentelsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Non-controlling Interest (Details) - USD ($)			12 Months Ended
Non-controlling Interest (Details) - USD ($)	Sep. 05, 2018	Sep. 05, 2018	Dec. 31, 2021	Dec. 31, 2020
Noncontrolling Interest
Equity Method Investment, Ownership Percentage			83.00%
Related Party Transaction, Expenses from Transactions with Related Party	$ 328,000
Research and Development Expense			$ 7,800,000	$ 5,131,000
Fair Value Of Shares Issued		$ 285,000
Net Income (Loss) Attributable to Noncontrolling Interest			(1,000)	(73,000)
Stock Purchase Agreement [Member]
Noncontrolling Interest
Research and Development Expense			$ 1,000	225,000
SYN Biomics [Member]
Noncontrolling Interest
Equity Method Investment, Ownership Percentage	88.50%	88.50%	100.00%
Equity interest by parent	11.50%	11.50%
Net Income (Loss) Attributable to Noncontrolling Interest				2,800,000
Synthetic Biomics Inc [Member]
Noncontrolling Interest
Equity interest by parent			17.00%
Dr. Pimentels [Member]
Noncontrolling Interest
Net Income (Loss) Attributable to Noncontrolling Interest				73,000,000,000
Dr. Pimentels [Member] \| Consolidation, Eliminations
Noncontrolling Interest
Net Income (Loss) Attributable to Noncontrolling Interest				$ 505,000
Cedarssinai Medical Center [Member]
Noncontrolling Interest
Number Of Common Stock To Be Issued	50,000	50,000
Number Of Common Stock To Be Held By Related Party	7,480,000	7,480,000
Cedarssinai Medical Center [Member] \| SYN Biomics [Member]
Noncontrolling Interest
Additional Number Of Common Stock To Be Issued	2,420,000	2,420,000
Cedarssinai Medical Center [Member] \| Synthetic Biomics Inc [Member]
Noncontrolling Interest
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	17.00%	17.00%